Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploid NK Cells for AML with MRD
NCT04209712Phase 1Unknown
- Sponsor
- Shanghai IxCell Biotech Co., Ltd.
- Start
- Jan 2020
- Primary completion
- Dec 2020
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in acute myeloid leukemia (AML), sponsored by Shanghai IxCell Biotech Co., Ltd. Primary endpoint: Minimal Residual Disease at 12 months. Status: unknown.
02
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04209712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04209712.